Anagenics (AN1) AI Stock Analysis

• Market Cap: AU$3.42M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: -54.87%
• EPS Growth: 86.17%
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 570,768,430
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.02
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.49
• P/FCF Ratio: -1.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: ―

The score is primarily constrained by weak financial performance—persistent losses, continued negative operating/free cash flow, and a significant latest-year revenue decline—despite only moderate leverage. Technical and valuation inputs were not available, so they were treated neutrally and did not materially offset the financial risks.

Positive Factors

Improved Cash Flow

Improved cash flow from restructuring indicates better financial management, enhancing the company's ability to fund operations and growth.

Strong Brand Performance

Strong brand performance, especially in Bouf Haircare, suggests robust market demand and potential for revenue growth.

Regained Control Over IP

Regaining control over Midkine IP allows Anagenics to independently commercialize and potentially expand its product offerings.

Negative Factors

Persistent Losses

Persistent losses and cash burn indicate financial instability, challenging the company's ability to sustain operations without external funding.

Revenue Decline

A significant revenue decline undermines growth prospects and pressures the company to stabilize its financial performance.

Negative Cash Flow

Consistently negative cash flow highlights reliance on external funding, posing risks to financial independence and long-term viability.

Anagenics Business Overview & Revenue Model

Company Description

Anagenics Limited operates as a health and beauty-tech company in Australia, New Zealand, Japan, and internationally. The company develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. It markets its products through various channels, including e-commerce, television shopping, wholesale pharmacy and salons, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

How the Company Makes Money

Anagenics generates revenue primarily through the sale of its proprietary health and wellness products in various markets. The company's revenue streams include direct sales to consumers through online platforms, partnerships with retail distributors, and collaborations with industry players to expand product reach. Anagenics may also engage in licensing agreements for its proprietary technologies and formulations, which could contribute to its revenue. Additionally, strategic partnerships with research institutions and other companies in the biotechnology and personal care sectors may play a role in boosting its earnings.

Anagenics Financial Statement Overview

Summary

Anagenics Limited faces challenges in achieving profitability and cash flow sustainability. Despite some revenue growth, the company struggles with negative profit margins and cash flow issues. The balance sheet shows conservative leverage but declining equity base, indicating potential financial instability if losses persist.

Income Statement

Anagenics Limited shows fluctuating revenue growth with an increase from 2023 to 2024, but overall profitability remains a challenge. The net profit margin is negative, and EBIT and EBITDA margins are also unfavorable, indicating operational inefficiencies. Despite some revenue growth, consistent losses impact financial stability.

Balance Sheet

The company's balance sheet indicates a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the equity ratio has deteriorated over time, and the ROE is negative due to ongoing net losses. This reflects a weakened capacity to generate returns on shareholder investments.

Cash Flow

Anagenics Limited has experienced negative operating and free cash flows, although there is a slight improvement in free cash flow. The company struggles to convert net income into cash flow, which indicates difficulties in managing cash effectively. Financing activities have been a significant source of cash inflow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.75M	4.75M	10.80M	9.11M	6.95M	5.82M
Gross Profit	2.04M	2.04M	4.36M	4.05M	3.80M	3.70M
EBITDA	-994.77K	-994.77K	-6.60M	-1.80M	-2.62M	-3.90M
Net Income	-1.24M	-1.24M	-7.49M	-2.67M	-3.65M	-3.39M
Balance Sheet
Total Assets	4.10M	4.10M	6.19M	11.11M	12.92M	13.29M
Cash, Cash Equivalents and Short-Term Investments	395.52K	395.52K	1.62M	2.57M	3.28M	6.73M
Total Debt	848.05K	848.05K	772.64K	654.33K	1.76M	1.43M
Total Liabilities	2.28M	2.28M	3.48M	2.22M	4.64M	2.86M
Stockholders Equity	1.83M	1.83M	2.71M	8.90M	8.29M	10.43M
Cash Flow
Free Cash Flow	-1.58M	-1.58M	-1.84M	-1.83M	-2.59M	-4.19M
Operating Cash Flow	-1.58M	-1.58M	-1.74M	-1.78M	-2.55M	-4.17M
Investing Cash Flow	0.00	0.00	-197.90K	-1.51M	-968.20K	477.53K
Financing Cash Flow	345.41K	345.41K	993.72K	2.56M	73.31K	3.50M

Anagenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
CLA	53 Neutral	AU$64.83M	-6.67	-11.03%	―	―	18.92%
AN1	44 Neutral	AU$3.42M	―	-54.48%	―	-54.87%	86.17%

Anagenics Corporate Events

Anagenics Appoints Connect National Audit as New External Auditor

Anagenics Limited has announced a change of auditor, with William Buck Audit (Vic) Pty Ltd resigning as the company’s auditor following consent from the Australian Securities and Investments Commission, effective 24 December 2025. Connect National Audit Pty Ltd has been appointed as the new auditor after receiving shareholder approval at the 2025 Annual General Meeting and subsequent ASIC consent, signaling a transition in Anagenics’ external audit oversight while the board expressed its appreciation for the outgoing firm’s service.

Anagenics Calls January 2026 Meeting to Ratify Share Placement

Anagenics Limited has called a general meeting of shareholders for 29 January 2026 in Sydney to consider ratifying a recent equity placement to sophisticated investors. The board is seeking shareholder approval under ASX Listing Rule 7.4 for the prior issue of 74,448,054 fully paid ordinary shares at $0.0046 per share, completed on 22 December 2025, which, if ratified, will restore the company’s placement capacity and provide greater flexibility for future capital management while formalising the terms of the recent fundraising.

Anagenics Seeks ASX Quotation for 74.4 Million New Shares

Anagenics Limited has applied to the ASX for quotation of 74,448,054 new fully paid ordinary shares under its AN1 ticker. The shares, issued on 22 December 2025 as part of a previously flagged transaction, will significantly expand the company’s quoted capital base, with potential implications for liquidity and ownership structure once trading commences.

Anagenics Files Cleansing Prospectus to Enable Trading of Placement Shares

Anagenics Limited has lodged a transaction-specific cleansing prospectus for a small offer of up to 100,000 new shares at $0.0046 each to raise a nominal $460, primarily to satisfy regulatory requirements rather than to fund operations. The document’s main purpose is to remove secondary trading restrictions on shares issued under a prior placement, enabling freer on‑market trading by existing investors while classifying the new shares as speculative, which shapes the company’s capital management flexibility and liquidity in its stock.

Anagenics Limited Announces Proposed Securities Issue

Anagenics Limited has announced a proposed issue of 414,682,381 ordinary fully paid securities, scheduled for February 5, 2026. This move is part of a placement or other type of issue, and the company has submitted the necessary information to the ASX for potential quotation of these securities. This announcement may impact Anagenics’ market operations by potentially increasing its capital base, which could be used for expansion or other strategic initiatives.

Anagenics Limited Announces Proposed Securities Issue

Anagenics Limited has announced a proposed issue of 74,448,054 ordinary fully paid securities, with the issuance date set for December 22, 2025. This move is part of a placement or other type of securities issue, and the company has applied for these securities to be quoted on the ASX. This announcement may impact Anagenics’ market position by potentially increasing its capital base, which could influence its operational capabilities and stakeholder interests.

Anagenics Limited Secures A$2.25 Million Through Share Placement

Anagenics Limited has announced a two-tranche placement to raise A$2.25 million by issuing approximately 489 million new shares at $0.0046 each, an 8% discount to the recent average price. The funds will support brand expansion, new business opportunities, debt reduction, and working capital. The placement, involving institutional and sophisticated investors, will occur in two stages, with the second tranche subject to shareholder approval. This strategic move aims to strengthen Anagenics’ market position and operational capabilities.

Anagenics Limited Initiates Trading Halt Ahead of Capital Raising Announcement

Anagenics Limited has requested a trading halt on its securities pending an announcement regarding a significant capital raising. The halt is expected to last until the announcement is made or until normal trading resumes on December 10, 2025. This move signals a strategic financial maneuver that could impact the company’s market positioning and stakeholder interests.

Anagenics Limited Successfully Passes All Resolutions at 2025 AGM

Anagenics Limited announced that all resolutions proposed at its 2025 Annual General Meeting were approved by the necessary majority. This includes the adoption of the remuneration report, re-election of a director, appointment of an auditor, and approval for additional placement capacity, reflecting strong shareholder support and potentially enhancing the company’s operational capabilities and market positioning.

Anagenics Limited Successfully Passes All Resolutions at 2025 AGM

Anagenics Limited announced that all resolutions proposed at its 2025 Annual General Meeting were passed by the requisite majority. The resolutions included the adoption of the remuneration report, re-election of a director, appointment of an auditor, and approval for additional placement capacity. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives in the beauty, health, and wellness sectors.

Anagenics Regains Control Over Midkine Portfolio Following Licence Termination

Anagenics Limited has announced the termination of its Licence Agreement with Lyramid Pty Ltd, now owned by Roquefort Therapeutics, regarding its Midkine intellectual property portfolio. This termination, effective from 2 November 2025, allows Anagenics to regain control over its Midkine products and intellectual property, enabling the company to further commercialize this product range independently. The extension of the transaction deadline between Roquefort Therapeutics and Pleiades Pharma Limited to 31 January 2026 does not affect Anagenics’ decision to terminate the agreement, potentially impacting its strategic positioning and operations in the market.

Anagenics Reports Improved Cash Flow and Strong Brand Performance

Anagenics Limited reported a significant improvement in operating cash outflows for the quarter ending September 2025, attributed to a successful business restructuring. The company reduced costs across staff, advertising, and administration, aligning with its post-restructure budget. York Street Brands, a division of Anagenics, saw strong performance with its Bouf Haircare line, projecting over $9 million in sales and exploring international market expansion. Anagenics is confident in its financial stability for the upcoming quarters and continues to seek growth opportunities.

Anagenics Limited Announces 2025 AGM Agenda

Anagenics Limited has announced its 2025 Annual General Meeting, scheduled for November 25, 2025, in Sydney. Key agenda items include the re-election of a non-executive director, adoption of the Remuneration Report, appointment of an auditor, and approval of additional placement capacity. Shareholders will have the opportunity to vote on these matters and engage with the board and auditor.